Overview

A Study of ABT-165 in Subjects With Solid Tumors

Status:
Active, not recruiting

Trial end date:
2023-10-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B, C and D is completed.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel